InspireMD, Inc. (NYSE:NSPR) has market cap of $4.8 million and holds 21.79 million shares outstanding. The stock accomplished trade value at $0.22 with -1.43% and traded volume 12769781 shares in recent trading period versus to an average volume of 2659.64K. The stock demonstrated move of 34.46% in previous 5 days graph. Its quarterly performance stands with the percentage of -56.94% while its year to date performance showed change of -95.09%.
The stock has monthly performance of 19.32% while its yearly performance remained at -98.20%. Its return on investment (ROI) for the last 12 months was -275.30% and its return on equity (ROE) of -291.80% while return on assets (ROA) is at -155.40%. The Company has an insider ownership of 5.71% and institutional ownership remained 12.10%.
InspireMD, Inc. (NYSE:NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of carotid artery disease, announced that preliminary cumulative three-year follow-up safety, efficacy and stroke prevention durability data from the PARADIGM-Extend trial of CGuard™ EPS was presented at the Cardiovascular Research Foundation’s Transcatheter Cardiovascular Therapeutics (TCT) 2018 conference, which was held September 21-25 in San Diego.
Overall cumulative data showed no stroke or stroke-related deaths between 24 and 36 months and the absence of any device related issues in the first 93 of the 251 patients in the PARADIGM-Extend cohort.
PARADIGM-Extend is the continuation of PARADIGM, an investigator-led clinical study evaluating the use of CGuard™ EPS in patients with symptomatic or asymptomatic carotid artery stenosis (CAD) with increased stroke risk.
“These preliminary three-year follow-up data continue to show very compelling safety, stroke prevention efficacy and long-term durability of CGuard™ EPS in an all-comer symptomatic and asymptomatic carotid artery stenosis patient population with various stages of disease progression,” said Prof. Piotr Musiałek, MD, Department of Cardiac and Vascular Diseases, John Paul II Hospital, Kraków, Poland, and lead investigator in the PARADIGM-Extend trial. “The risk of stroke and other serious complications post-procedure remains a significant consideration in the treatment of CAS, and these results reflect the sustained, long term potential of CGuard™ EPS to significantly improve patient outcomes and evolve into the new standard of care.”
“We are grateful to Prof. Musiałek for his continued interest in CGuard™ EPS for treating all his patients with carotid artery disease, and we are pleased that the data from this investigator-led study continues to demonstrate strong safety and efficacy up to 36 months post-procedure,” said James Barry, PhD, Chief Executive Officer of InspireMD. “With this latest presentation, we are compiling a significant body of evidence suggesting that treatment with CGuard™ EPS could result in sustained, long term normal vessel healing with no device-related issues. We look forward to the presentation of additional three-year data at the 45th Annual Symposium on Vascular and Endovascular Issues, Techniques, Horizons (VEITHsymposium) in New York in November.”